US FDA Approves Rhizomfy Eye Drops for Presbyopia in Adults

The US Food and Drug Administration has approved Phentolamine 0.75% eye drops (Rhizomfy) for the treatment of presbyopia in adults, according to an announcement from Opus Genetics. The approval expands the use of the previously approved drug, and is based on the Phase 3 VEGA-2 and VEGA-3 trials.

AI-written summary of 6 sources; every verified point is backed by a verbatim quote. How Iyan works

• The approval for the drug's use in presbyopia is based on the Phase 3 VEGA-2 and VEGA-3 trials.

  «Phentolamine 0.75% (Ryzumvi) won FDA approval for presbyopia based on the phase 3 VEGA-2 and VEGA-3 trials.»

  The American Journal of Managed Care
• The drug was previously approved to treat drug-induced pupil dilation in adults and children aged 3 years and older.

  «The medication is currently approved to treat pharmacologically induced mydriasis, or pupil dilation, in adults and children ages 3 years or older.»

  Medscape
• Opus Genetics announced that the approval was granted on a supplemental application for Phentolamine Ophthalmic Solution 0.75% (Rhizomfy).

  «Opus Genetics announced that the FDA approved its supplemental new drug application for phentolamine ophthalmic solution 0.75% (Ryzumvi)»

  Eyewire+
• Opus Genetics is a clinical-stage biopharmaceutical company developing gene therapies to restore vision in patients with inherited retinal diseases.

  «a clinical-stage biopharmaceutical company developing gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases (IRDs)»

  visionmonday.com

Iyan — See it for yourself. What changed in your world today, why it matters, and how we know.
How it works • Privacy • Terms